1003845-06-4

Basic information

• Product Name: 2-CHLOROPYRIMIDINE-5-BORONIC ACID
• Synonyms: 2-CHLOROPYRIMIDINE-5-BORONIC ACID;2-chloropyrimidin-5-ylboronic acid;2-CHLORO-5-PYRIMIDINEBORONIC ACID;2-Chloropyrimidine-5-boro...;2-Chloro-pyridineyl-5-boronic;2-Chloro-pyridineyl-5-boronic acid;2-ChloropyriMidine-5-boronic acid (contains varying aMounts of anhydride);2-CHLOROPYRIMIDINE-5-BORONIC ACID###1003845-06-4
• CAS NO: 1003845-06-4
• Molecular Formula: C₄H₄BClN₂O₂
• Molecular Weight: 158.35076
• Product Categories: Heterocyclic Compounds;Organoborons;Pyrimidine
• Mol File: 1003845-06-4.mol

Chemical Properties

• Boiling Point: 425.36 °C at 760 mmHg
• Flash Point: 211.051 °C
• Appearance: White/Powder
• Density: 1.522 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 5.03±0.11(Predicted)
• CAS DataBase Reference: 2-CHLOROPYRIMIDINE-5-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLOROPYRIMIDINE-5-BORONIC ACID(1003845-06-4)
• EPA Substance Registry System: 2-CHLOROPYRIMIDINE-5-BORONIC ACID(1003845-06-4)

Safety Data

• Hazardous Substances Data: 1003845-06-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C4H4BClN2O2/c6-4-7-1-3(2-8-4)5(9)10/h1-2,9-10H

Upstream product

• 5419-55-6 Triisopropyl borate 
• 32779-36-5 5-Bromo-2-chloropyrimidine 

Downstream Products

• 1003845-08-6 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine 
• 1155877-93-2 C₁₈H₁₃Cl₂FN₂O 
• 1202190-99-5 Methyl-[5-(4-chlorophenyl)-1-(2-chloropyrimidin-5-yl)-3-methyl-1H-pyrazol-4-yl]acetate 
• 4983-28-2 2-chloropyrimidine-5-ol 
• 870521-33-8 [2-(morpholin-4-yl)pyrimidin-5-yl]boronic acid 
• 859209-15-7 5-benzyl-2-chloropyrimidine 
• 1312942-15-6 2-(2-methoxyethylamino)pyrimidin-5-ylboronic acid 
• 1580440-74-9 2-chloro-5-(4-(2-methoxyethoxy)benzyl)pyrimidine 

Relevant articles and documents

Development of a concise scaleable synthesis of 2-chloro-5-(pyridin-2-yl) pyrimidine via a Negishi cross-coupling

A practical and scaleable synthesis of 2-chloro-5-(pyridin-2-yl) pyrimidine, an intermediate in the synthesis of a selective PDE-V inhibitor, was developed. A Negishi cross-coupling between the in situ prepared 2-pyridylzinc chloride and 5-iodo-2-chloropyrimidine catalyzed by Pd(PPh3)4 afforded the product in one step. Development of a convenient purification did away with the necessity of chromatography, allowing the preparation of the product on kilogram scale.

NOVEL COMPOUNDS AS GPR119 AGONISTS

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

Double Suzuki cross-coupling reaction of pyrimidine boronic acid: Synthesis of new versatile dielectrophile

The double Suzuki cross-coupling reaction has successfully been applied for the synthesis of 5,5'-(5-butoxy-1,3-phenylene)bis(2-chloropyrimidine) with two reactive chloro groups and an alkoxy side chain starting from 2-chloropyrimidin-5-ylboronic acid and 1,3-dibromo-5-butoxybenzene. The reactivity of this dielectrophile was tested by reaction with aniline and phenol, a nitrogen and oxygen nucleophile, respectively. The new dielectrophile would further provide an ideal platform for the construction of large hetero-atom bridged macrocycles for desired properties and functions in supramolecular and material chemistry. Copyright

TYROSINE KINASE INHIBITORS

The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS

The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: A particular embodiment is

AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS

The present invention provides a compound of formula (I), wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

New pyrimidylboronic acids and functionalized heteroarylpyrimidines by Suzuki cross-coupling reactions

We report the synthesis of 2-chloro-5-pyrimidylboronic acid (6) and 2-amino-5-pyrimidylboronic acid (8) by lithium-halogen exchange followed by reaction with triisopropylborate. Their reactivity with heteroaryl halides in Suzuki-Miyaura cross-coupling reactions has been evaluated. New highly functionalized 5-heteroarylpyrimidine derivatives 24-33 (heteroaryl = quinoline, pyridine, pyrimidine, pyrazine, thiophene, benzothiazole) have been obtained in synthetically useful yields. The X-ray structure of 6 reveals extensive intermolecular O-H...N hydrogen bonding in the crystal. Wiley-VCH Verlag GmbH & Co. KGaA, 2007.